Anticancer Fund

Rethinking Cancer Treatment: when less may be more What if giving cancer patients lower doses could actually help them live longer with fewer side effects? 🔬 New research published in Cancer Research challenges the traditional "maximum dose" approach to cancer treatment. Instead of hitting cancer cells with the highest possible doses, adaptive therapy adjusts treatment based on tumor response—maintaining a balance between drug-sensitive and drug-resistant cancer cells. The science behind it: ✓ Drug-sensitive cancer cells are more competitive than resistant ones when treatment pressure is removed ✓ By keeping sensitive cells alive, they naturally suppress resistant cell growth ✓ Mouse studies show longer survival with adaptive therapy vs. standard treatment Real-world application: Anticancer Fund is supporting the ACTOv clinical trial for advanced ovarian cancer patients in the UK, led by Professor Michelle Lockley at Queen Mary University of London. 💬 As Prof. Lockley explains: "Patients are very open to the idea that we may be able to achieve better control of their cancer with lower drug doses and fewer side effects." This research represents a shift from viewing cancer as an enemy to destroy at all costs, to managing it as a chronic condition. It's about working with cancer's evolutionary dynamics rather than against them. 💥 The implications extend beyond ovarian cancer—this approach could benefit many cancer types, especially those with effective targeted therapies and measurable resistance markers. What do you think? ⁉️ Could this approach change how we think about cancer treatment? 👉 Read all about adaptive therapy on the website of Anticancer Fund: https://lnkd.in/e2AM2qJQ Or read a full interview with Professor Michelle Lockley right here in the article below 👇 #anticancerfund #cancerresearch Barts Cancer Institute (Queen Mary University of London) The Institute of Cancer Research

We're hiring a Junior Research Manager at Anticancer Fund! Imagine if every literature search you conducted could directly impact someone's cancer journey. That's exactly what you'll do here – transforming complex medical research into clear, compassionate guidance that helps real people make informed decisions about their cancer treatment. What makes this role special? ✨ Direct patient impact – Your work directly supports people navigating cancer 📈 Growth-focused – Mentorship from senior researchers and medical doctors 🤝 Collaborative culture – Small, supportive team where your ideas matter ⚖️ Work-life balance – Flexible hours + 2 days WFH + part-time options You'll be perfect if you have: ✔️ Master's in Biomedical Sciences, Pharmacy, Medicine, or similar ✔️ Evidence-based research skills (PubMed, systematic searches, literature reviews) ✔️ Ability to translate complex science into patient-friendly language ✔️ Professional English + French/Dutch is a plus ✔️ Empathy and collaborative spirit Ready to turn your research skills into real-world impact? 💪 📋 Full job details: https://lnkd.in/dy9DKss Send your CV and motivation letter to jobs@anticancerfund.org with subject "Junior Research Manager" #anticancerfund #mycancernavigator #jobopening #vacancy

We're #hiring a new Junior Research Manager - My Cancer Navigator in Meise, Flemish Region. Apply today or share this post with your network.

🎙️ Making Our Voice Heard for Cancer Patients in Europe Today, LYDIE MEHEUS of Anticancer Fund had the privilege of presenting at the European Parliament's public hearing on pharmaceutical legislation reform - a critical moment for shaping the future of cancer care across Europe. 🗝️ Our key message was clear: Drug repurposing represents a promising and complementary strategy for medical innovation that can deliver real benefits to patients and society. However, this approach requires a supportive ecosystem that recognises and adequately supports the vital role of non-commercial actors. 🔬 Why this matters: Non-commercial research organisations like Anticancer Fund often drive innovation in areas where traditional commercial incentives fall short - particularly in rare cancers and childhood cancers where patient populations are smaller but needs are just as urgent. 💡 The game-changer: Article 48 of the proposed EU Pharmaceutical Regulation could be transformative. If implemented, it will create a clear pathway for translating clinical evidence from non-commercial trials into real-world clinical practice, directly benefiting patients who need these treatments. 👉 A big thank you to the co-chairs MEP Tomislav Sokol, MEP Vlad Voiculescu, MEP Tilly Metz, MEP Stine Bosse, and MEP ALESSANDRA MORETTI for emphasising that we must look beyond just the pharmaceutical package. As they noted, addressing unmet medical needs requires examining the entire ecosystem - from cross-border clinical trials to research conditions and public funding. Their message resonated deeply. 🤝 Thank you to all stakeholders who participated in this important dialogue. #cancerresearch #drugrepurposing #anticancerfund REMEDi4ALL Patricia Vandamme

Symposium Patient Value in Oncology Research & Care United for Change: Transdisciplinary Paths to Patient Value in Oncology 💚 Join us for a unique gathering of minds committed to advancing patient value in oncology. This closure event will be the occasion to share what we have learned during the Symphony of Us project and to bridge our findings and experiences with yours. Let’s further explore, discuss, and inspire new ways of putting patient value at the heart of oncology research and practice together! 📆 November 25th 2025 📍 USquare Brussels, Kroonlaan 227, 1050 Elsene 🖋️ Register here: https://lnkd.in/gaehdv-E Are you also driven by Patient Value in oncology, share what you do by submitting an abstract! 📣 Abstract Submission is Open 🔒 Deadline: 01/09/2025 📬 Submission: https://lnkd.in/gAYdsEa9 Hope to see you there! Florence Horicks Silke Leonard Brent Taels Teodora Lalova-Spinks King Baudouin Foundation

👉 July is Sarcoma Awareness Month When looking at the news headlines announcing impressive breakthroughs and new treatment options in cancer, it is easy to imagine that progress is happening across the board and that things are improving in all cancer types. 🔬 But sadly that is not the case – while it’s a positive picture in some areas in others the truth is that there has been no progress in decades. This is particularly true when it comes to the family of cancers called sarcomas. 😪 These are cancers of the connective tissues such as bone, cartilage and blood vessels, and are often still being treated as they were 30 or more years ago. So let’s use sarcoma awareness month to say it loud and clear. 📢 ✔️ Read more about why sarcoma is a large unmed need: https://lnkd.in/eeRqAX3 ✔️ Read more about a trial we fund, together with EORTC - European Organisation for Research and Treatment of Cancer: https://lnkd.in/edAH8_w3 #anticancerfund

Juli = Sarcoom Awareness Month 🎗 Een maand waarin ik – nu 47 – even stilsta bij iets dat al sinds mijn 23e een deel van mijn leven is: synoviaal sarcoom, een zeldzame en vaak vergeten kanker. 💬 “Als sarcoompatiënt sta je vaak als laatste in de rij.” Ik gaf vorig jaar een interview over wat het betekent om met een zeldzame kanker te leven. Een sluipmoordenaar die vaak te laat wordt herkend. In mijn geval begon het met een zwelling onder de oksel. De huisarts dacht aan een vetbolletje. Gelukkig had mijn moeder twijfels. Uiteindelijk kwam de diagnose: sarcoom. 💪 23 jaar na de diagnose heb ik veel meegemaakt – lichamelijk én mentaal – maar ik ben er nog altijd, met meer veerkracht dan ooit. 📺 Daarom startte ik ‘Klare Kijk op Kanker’: een platform dat kankerpatiënten op een positieve, toegankelijke manier helpt om grip te krijgen op hun traject. Geen medische taal of zwart-witverhalen, maar herkenbare stemmen van mensen die hetzelfde meemaken. 🙏 Dank aan All.Can Belgium en MSD Belgium voor het vertrouwen. En dank aan iedereen die zich inzet voor betere, menselijkere kankerzorg. 📣 Deel deze post en help mee de stilte rond zeldzame kankers te doorbreken. Want bewustwording redt levens. #SarcoomAwarenessMonth #ZeldzameKanker #KlareKijkOpKanker #PatientEmpowerment #KankerHeeftVeleGezichten #Bewustwording

It’s been a great honor to present at the European Pancreatic Club 2025 in Düsseldorf, where I delivered two lectures: 🔹 State-of-the-art: Personalizing Pancreatic Cancer Treatments 🔹 Optimizing Treatment Selection in Pancreatic Cancer. The Contribution of Preclinical Models Preparing these conferences has been especially meaningful, as it led me, together with Prof. Pascal Hammel and colleagues from the Club Français du Pancréas, to write a comprehensive review now published in "Cancer Treatment Reviews" were we extensively develop the concepts and data I presented during the EPC meeting. Feel free to read our review for a deeper dive into these topics! “Medical management of pancreatic cancer: from personalization to broadening treatment strategies”. 🔗 https://lnkd.in/ezQ2HEcr I warmly thank the European Pancreatic Club, the Anticancer Fund and Pancreatic Cancer Europe for the invitation and support, and for the excellent organization and inspiring discussions. #EPC2025 #PancreaticCancer #PrecisionMedicine #TranslationalResearch #PreclinicalModels

The kick-off meeting of the FORCE consortium (Fostering Oncology Research by Charities in Europe) was a success in Paris yesterday. The Anticancer Fund, proud of this united effort, was there together with 13 other partners from the non-profit sector to launch this project that represents the start of new possibilities for patients with cancers. Thanks to Gauthier B., our Director of Clinical Research, for moderating the panel discussion on pragmatic trials. Our sincere gratitude to Fondation ARC pour la recherche sur le cancer for making this event and project possible, and to the European Commission for funding this project that will make a meaningful impact on the lives of cancer patients. FORCE partners Fondation ARC pour la recherche sur le cancer Fundación Científica de la Asociación Española Contra el Cáncer Anticancer Fund Kom op tegen Kanker  KWF Kankerbestrijding Barncancerfonden  Cancerfonden Fundacja Na Ratunek Dzieciom z Chorobą Nowotworową Latvian Children’s Oncology Foundation  AIRC - Foundation for Cancer Research NGO Breakthrough Cancer Research Irish Cancer Society Ελληνική Αντικαρκινική Εταιρεία- Hellenic Cancer Society Hungarian League Against Cancer

On Saturday, July 5th, our colleague Ilse Rooman will co-lead a session with Costello-Goldring Eithne at the European Pancreatic Club annual meeting. 🧬 "Bridging the gap: from preclinical discoveries to clinical trials in pancreatic cancer" 🔬➡️🏥 Pancreatic cancer remains one of the most challenging diseases to treat, with many clinical trials failing to deliver expected results. This session addresses an important issue in cancer research: the disconnect between promising laboratory findings and successful patient treatments. 💡 Key areas of focus include: - Better understanding of tumor biology 🧪 - Development of preclinical models that reflect clinical reality - Rigorous preclinical testing before moving to clinical trials 📊 - Comprehensive analysis of patient samples in clinical research The session aims to present both research successes and the obstacles that researchers encounter. While preclinical research in pancreatic cancer generates hope, translating these discoveries into effective treatments involves scientific, financial, and regulatory challenges that need to be better understood. 🤝 This discussion is an important step toward developing more effective strategies for moving from laboratory discoveries to treatments that effective benefit patients. 🎯 #anticancerfund #cancerresearch PCE Pancreatic Cancer Europe